|By PR Newswire||
|February 12, 2014 09:43 AM EST||
NEW YORK, Feb. 12, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012
PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012
"PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012" report provides an in-depth understanding of the key deals that took place in the region during the last decade. The type of deals covered in the report include Mergers & Acquisitions (M&A), Licensing and Collaboration & Partnerships.
The report also provides understanding on the regional differences in the deal making activity to that of the global trends and key trends are outlined with insight on drivers such as regulatory policy, macro-economic and industry factors as well as market access challenges. Case studies including the top five deals in value among Mergers & Acquisition, Licensing and Collaboration & Partnerships are strategically analyzed to provide comprehensive understanding on areas such as structure and status of the deal vis a vis the overall corporate strategy.
Key Questions Answered
- How are the main deal categories faring among top countries in the Latin America region over the past five years?
- What are the primary reasons for increased activity in strategic deals by leading pharmaceutical companies in LATAM region?
- What are the key trends, and strategies involved in M&As, licensing deals, and collaboration agreements entered into by leading pharmaceutical and healthcare companies in the Latin American region?
- What strategies are the most successful companies pursuing to gain and maintain their market leading position?
- Which are the key companies that are potential targets of acquisitions?
- Report provides in-depth understanding of the key pharmaceutical and healthcare deals that took place in the LATAM region during the past five years. Furthermore, key deals are discussed from a domestic and global point of view.
- Current regulatory framework in various markets in LATAM including recent and/or ongoing developments that are expected to impact or influencing the industry are discussed. In-depth commentary on four countries in the region are included.
- Highly Insightful analyses on the deal making terms, strategic implications and synergies of recent deals activity in the LATAM pharmaceutical industry.
- Collaboration & Acquisition Strategies: Exhaustive discussion on the strategic implications and synergies of recent M&A and partnering activities. Case Studies of five deals are included in each deal category.
- Expert Insights on the corporate strategies of various drug companies seeking a competitive advantage in the pharmaceutical market place.
- Five major regional companies are profiled providing an in-depth analysis on their individual deal making strategies.
- Number of Case Studies on top deal making activities shedding light on rationale and strategy. Potential targets for acquisitions in the region are also identified.
Reasons to buy
- Understand the primary drivers behind major deal initiatives in the LATAM region.
- Analyze the structure of the deals and gain insight on the various factors considered when structuring deal terms in strategic acquisitions, mergers, collaborations, and licensing.
- Identify rationale behind potential takeover targets and partners, thereby maximizing your opportunities for consolidation, investment, and strategic partnerships in the Asia Pacific region.
- Use this information as an independent source for your due diligence and transaction strategy.
1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 10
1.2 List of Figures 12
2 Introduction 14
2.1 Report Scope 14
2.1.1 Key Questions Answered 14
2.1.2 Key Benefits 15
2.1.3 Upcoming Related Reports 15
3 Historical Dealmaking Trends 16
3.1 Overview 16
3.2 Leading Deal Drivers 17
3.2.1 Dampening Global Pharmaceutical Markets 17
3.2.2 Intellectual Property Issues and Rising Competition 18
3.2.3 Universal Healthcare Access, Primary Healthcare, and Health Insurance 19
3.2.4 Increasing Consolidation 20
3.3 Overall Deals in Review 21
3.3.1 Review by Deal Type 21
4 Regional Country Profiles 28
4.1 Brazil 28
4.1.1 Overview 28
4.1.2 Top Deals by Value and Volume 29
4.1.3 Market Dynamics 31
4.2 Mexico 34
4.2.1 Overview 34
4.2.2 Top Deals by Value and Volume 35
4.2.3 Market Dynamics 37
4.3 Argentina 41
4.3.1 Overview 41
4.3.2 Top Deals by Value and Volume 42
4.3.3 Market Dynamics 44
4.4 Venezuela 48
4.4.1 Overview 48
4.4.2 Top Deals by Value and Volume 49
4.4.3 Market Dynamics 51
5 Mergers and Acquisitions 55
5.1 Overview 55
5.2 Case Studies 57
5.2.1 UnitedHealth Group Acquires Amil Participações 57
5.2.2 Hypermarcas Acquires Mantecorp Indústria Química e Farmacêutica 59
5.2.3 Hypermarcas Acquires Laboratório Neo Química 60
5.2.4 Acquisition of Lafrancol (Colombia) by Recalcine (Chile) 61
5.2.5 Sanofi Aventis Acquires Medley Indústria Farmacêutica 62
6 Licensing Agreements 64
6.1 Overview 64
6.2 Case Studies 66
6.2.1 FBM Indústria Farmacêutica (FBM Farma) Enters into Licensing Agreement with Ampio Pharmaceuticals 66
6.2.2 FAES Farma and Pfizer Expand Bilastine License Agreement 67
6.2.3 CEL-SCI Enters into Licensing Agreement with IDC-GP Pharm 68
6.2.4 Vanda Pharma Enters into Licensing Agreement with Biotoscana Farma 70
6.2.5 Oxford Nutrascience Enters into Licensing Agreement with Aché Laboratórios 71
7 Collaborations and Partnerships 73
7.1 Overview 73
7.2 Case Studies 75
7.2.1 Pfizer Enters into an Agreement with Laboratório Teuto Brasileiro 75
7.2.2 Avesthagen Forms a Joint Venture with Uxmal 77
7.2.3 Baxter International Enters into Agreement with Hemobras for Recombinant Factor VIII (rFVIII) Hemophilia Treatment 78
7.2.4 Cristalia, Biolab, Eurofarma, and Libbs Enter into Joint Venture for Biological Medicines 80
7.2.5 Aché , Uniao Química Farmacêutica, Hypermarcas, and EMS Laboratories Set Up a Joint Venture 81
8 Deal Strategy of Major LATAM Companies 83
8.1 Amil Participações S.A. 83
8.1.1 Recent Deals: M&As, Licensing, and Partnerships 83
8.1.2 Overall Deal Strategy 84
8.2 Hypermarcas 85
8.2.1 Recent Deals: M&As, Licensing, and Partnerships 85
8.2.2 Overall Deals Strategy 86
8.3 Grupo Casa Saba 87
8.3.1 Recent Deals: M&As, Licensing, and Partnerships 87
8.3.2 Overall Deals Strategy 87
8.4 Genomma Lab Internacional 88
8.4.1 Recent Deals: M&As, Licensing, and Partnerships 88
8.4.2 Overall Deals Strategy 88
8.5 CFR Pharmaceuticals 89
8.5.1 Recent Deals: M&As, Licensing, and Partnerships 89
8.5.2 Overall Deals Strategy 90
9 Future Outlook 91
9.1 Overview 91
9.2 Deal-Making Trends 91
9.2.1 Mergers and Acquisitions 91
9.2.2 Licensing and Partnership Deals to Rise in Quest for Portfolio and Pipeline Growth 93
9.2.3 Market Access Challenges will Impact Deal Activity 93
10 Appendix 95
10.1 Bibliography 95
10.2 Abbreviations 97
10.3 About the Author 100
10.3.1 Industry Analyst 100
10.4 Director of Healthcare Industry Dynamics 100
10.5 Global Head of Healthcare 101
10.6 About the Industry Dynamics Team 101
10.7 About GlobalData 101
10.8 Disclaimer 102
1.1 List of Tables
Table 1: Overview of Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Brazil, 2008-2012 29
Table 2: Market Share Split of Pharma Firms in Brazil 33
Table 3: Overview of the Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Mexico, 2008-2012 35
Table 4: Pharmaceutical Market, Mexico, Forecast ($bn), 2011-2020 38
Table 5: Top 10 Pharma Firms in Mexico Revenue-Wise 39
Table 6: Top Healthcare Distribution Firms in Mexico Revenue-Wise 40
Table 7: Overview of the Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Argentina, 2008-2012 42
Table 8: Pharmaceutical Market, Argentina, Revenue ($bn), Forecast, 2013-2020 45
Table 9: Top 10 Pharma Firms in Argentina, Revenue-Wise 46
Table 10: Overview of the Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Venezuela, 2008-2012 49
Table 11: Pharmaceutical Market ($bn), Venezuela, Forecast, 2012-2020 52
Table 12: Top 10 M&A Deals by Value, LATAM Region, 2008-2012 56
Table 13: UnitedHealth Acquires Amil Participações 57
Table 14: Hypermarcas Acquires Mantecorp 59
Table 15: Hypermarcas Acquires Laboratório Neo Química Comércio e Indústria 60
Table 16: Recalcine Acquires Lafrancol 61
Table 17: Sanofi Aventis Acquires Medley Indústria Farmacêutica 62
Table 18: Major Licensing Deals, LATAM Region, 2008-2012 64
Table 19: FBM Farma Indústria Farmacêutica Licenses Zertane from Ampio Pharmaceuticals 66
Table 20: Pfizer and Faes Farma in Licensing Deal for Bilastine 67
Table 21: CEL-SCI Enters into Licensing Agreement with IDC-GP Pharm 68
Table 22: Vanda Pharma Enters into Licensing Agreement with Biotoscana Farma 70
Table 23: Oxford Nutrascience Enters into Licensing Agreement with Ache Laboratórios 71
Table 24: Top 10 Collaboration and Partnership Deals in the LATAM Region, 2008-2012 74
Table 25: Pfizer Enters Into An Agreement With Laboratório Teuto Brasileiro 75
Table 26: Avesthagen Enters into Agreement with Uxmal 77
Table 27: Baxter International Enters Into Agreement With Hemobras 78
Table 28: Cristalia, Biolab, Eurofarma and Libbs Enter into Joint Venture 80
Table 29: Aché , Uniao Química Farmacêutica , Hypermarcas, and EMS Laboratories Set Up a Joint Venture 81
Table 30: Amil Participações ' Recent Deals Activity 83
Table 31: Hypermarcas' Recent Deals Activity 85
Table 32: Grupo Casa Saba's Recent Deals Activity 87
Table 33: Genomma Lab Internacional's Recent Deals Activity 88
Table 34: CFR Pharmaceuticals' Recent Deals Activity 89
List of Figures
Figure 1: Foreign Direct Investment Flow, LATAM Region, 2011-2012 17
Figure 2: Research and Development Spending of PhRMA Members, 2005-2012 18
Figure 3: Trend in M&A Deal Volume, LATAM Region, 2008-2012 22
Figure 4: Trend in M&A Deal Values, LATAM Region, 2008-2012 23
Figure 5: Volume of Licensing Deals, LATAM Region, 2008-2012 24
Figure 6: Trend in Licensing Deal Values, LATAM Region, 2008-2012 25
Figure 7: Trend in Collaboration and Partnership Deal Volumes, LATAM Region, 2009-2012 26
Figure 8: Trend in Collaboration and Partnership Deal Values, LATAM Region, 2009-2012 27
Figure 9: Trends in Deal Volume in Brazil, 2008-2012 30
Figure 10: Volume of Deal Types in Brazil, 2008-2012 31
Figure 11: Pharmaceutical Market, Brazil, Revenue ($bn), Forecast, 2013-2020 32
Figure 12: Trends in Deal Volume in Mexico, 2008-2012 36
Figure 13: Volume of Deal Types in Mexico, 2008-2012 37
Figure 14: Trend in Market Forecast in Mexico, 2011-2020 38
Figure 15: Trends in Deal Volume in Argentina, 2008-2012 43
Figure 16: Volume of Deal Types in Argentina, 2008-2012 44
Figure 17: Pharmaceutical Market, Argentina, Revenue ($bn), Forecast, 2013-2020 45
Figure 18: Trends in Deal Volume in Venezuela, 2009-2012 50
Figure 19: Trends in Volume of Deal Types in Venezuela, 2009-2012 50
Figure 20: Pharmaceutical Market ($bn), Venezuela, Forecast, 2012-2020 52
Figure 21: Number of M&A Deals in Major Countries, LATAM Region, 2008-2012 57
Figure 22: Split in Volume of Licensing Deals among Drug Development Phases, LATAM Region, 2008-2012 65
To order this report: PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012
Contact Clare: [email protected]
Intl: +1 339-368-6001
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smar...
Oct. 28, 2016 12:15 PM EDT Reads: 1,296
President Obama recently announced the launch of a new national awareness campaign to "encourage more Americans to move beyond passwords – adding an extra layer of security like a fingerprint or codes sent to your cellphone." The shift from single passwords to multi-factor authentication couldn’t be timelier or more strategic. This session will focus on why passwords alone are no longer effective, and why the time to act is now. In his session at 19th Cloud Expo, Chris Webber, security strateg...
Oct. 28, 2016 12:02 PM EDT
As companies adopt the cloud-to-streamline workflow, deployment hasn’t been very seamless because of IT concerns surrounding security risks. The cloud offers many benefits, but protecting and securing information can be tricky across multiple cloud providers and remains IT’s overall responsibility. In his session at 19th Cloud Expo, Simon Bain, CEO of SearchYourCloud, will address security compliance issues associated with cloud applications and how document-level encryption is critical for sup...
Oct. 28, 2016 12:00 PM EDT Reads: 427
In past @ThingsExpo presentations, Joseph di Paolantonio has explored how various Internet of Things (IoT) and data management and analytics (DMA) solution spaces will come together as sensor analytics ecosystems. This year, in his session at @ThingsExpo, Joseph di Paolantonio from DataArchon, will be adding the numerous Transportation areas, from autonomous vehicles to “Uber for containers.” While IoT data in any one area of Transportation will have a huge impact in that area, combining sensor...
Oct. 28, 2016 12:00 PM EDT Reads: 1,227
SYS-CON Events announced today that Tintri Inc., a leading producer of VM-aware storage (VAS) for virtualization and cloud environments, will present at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Tintri VM-aware storage is the simplest for virtualized applications and cloud. Organizations including GE, Toyota, United Healthcare, NASA and 6 of the Fortune 15 have said “No to LUNs.” With Tintri they manag...
Oct. 28, 2016 12:00 PM EDT Reads: 3,685
In his general session at 19th Cloud Expo, Manish Dixit, VP of Product and Engineering at Dice, will discuss how Dice leverages data insights and tools to help both tech professionals and recruiters better understand how skills relate to each other and which skills are in high demand using interactive visualizations and salary indicator tools to maximize earning potential. Manish Dixit is VP of Product and Engineering at Dice. As the leader of the Product, Engineering and Data Sciences team a...
Oct. 28, 2016 12:00 PM EDT Reads: 935
DevOps is speeding towards the IT world like a freight train and the hype around it is deafening. There is no reason to be afraid of this change as it is the natural reaction to the agile movement that revolutionized development just a few years ago. By definition, DevOps is the natural alignment of IT performance to business profitability. The relevance of this has yet to be quantified but it has been suggested that the route to the CEO’s chair will come from the IT leaders that successfully ma...
Oct. 28, 2016 11:45 AM EDT Reads: 16,667
We are always online. We access our data, our finances, work, and various services on the Internet. But we live in a congested world of information in which the roads were built two decades ago. The quest for better, faster Internet routing has been around for a decade, but nobody solved this problem. We’ve seen band aid approaches like CDNs that attack a niche's slice of static content part of the Internet, but that’s it. It does not address the dynamic services-based Internet of today. It doe...
Oct. 28, 2016 11:30 AM EDT Reads: 2,107
Join IBM November 2 at 19th Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA, and learn how to go beyond multi-speed it to bring agility to traditional enterprise applications. Technology innovation is the driving force behind modern business and enterprises must respond by increasing the speed and efficiency of software delivery. The challenge is that existing enterprise applications are expensive to develop and difficult to modernize. This often results in what Gartner calls...
Oct. 28, 2016 11:30 AM EDT Reads: 212
Although it has gained significant traction in the consumer space, IoT is still in the early stages of adoption in enterprises environments. However, many companies are working on initiatives like Industry 4.0 that includes IoT as one of the key disruptive technologies expected to reshape businesses of tomorrow. The key challenges will be availability, robustness and reliability of networks that connect devices in a business environment. Software Defined Wide Area Network (SD-WAN) is expected to...
Oct. 28, 2016 11:00 AM EDT Reads: 2,276
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
Oct. 28, 2016 11:00 AM EDT Reads: 360
Bert Loomis was a visionary. This general session will highlight how Bert Loomis and people like him inspire us to build great things with small inventions. In their general session at 19th Cloud Expo, Harold Hannon, Architect at IBM Bluemix, and Michael O'Neill, Strategic Business Development at Nvidia, will discuss the accelerating pace of AI development and how IBM Cloud and NVIDIA are partnering to bring AI capabilities to "every day," on-demand. They will also review two "free infrastruct...
Oct. 28, 2016 10:32 AM EDT Reads: 241
The Internet of Things (IoT), in all its myriad manifestations, has great potential. Much of that potential comes from the evolving data management and analytic (DMA) technologies and processes that allow us to gain insight from all of the IoT data that can be generated and gathered. This potential may never be met as those data sets are tied to specific industry verticals and single markets, with no clear way to use IoT data and sensor analytics to fulfill the hype being given the IoT today.
Oct. 28, 2016 10:30 AM EDT Reads: 2,957
@ThingsExpo has been named the Top 5 Most Influential M2M Brand by Onalytica in the ‘Machine to Machine: Top 100 Influencers and Brands.' Onalytica analyzed the online debate on M2M by looking at over 85,000 tweets to provide the most influential individuals and brands that drive the discussion. According to Onalytica the "analysis showed a very engaged community with a lot of interactive tweets. The M2M discussion seems to be more fragmented and driven by some of the major brands present in the...
Oct. 28, 2016 09:15 AM EDT Reads: 11,630
Fact: storage performance problems have only gotten more complicated, as applications not only have become largely virtualized, but also have moved to cloud-based infrastructures. Storage performance in virtualized environments isn’t just about IOPS anymore. Instead, you need to guarantee performance for individual VMs, helping applications maintain performance as the number of VMs continues to go up in real time. In his session at Cloud Expo, Dhiraj Sehgal, Product and Marketing at Tintri, wil...
Oct. 28, 2016 09:00 AM EDT Reads: 2,037